» Articles » PMID: 34073826

Environmental Factors-Induced Oxidative Stress: Hormonal and Molecular Pathway Disruptions in Hypogonadism and Erectile Dysfunction

Overview
Date 2021 Jun 2
PMID 34073826
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Hypogonadism is an endocrine disorder characterized by inadequate serum testosterone production by the Leydig cells of the testis. It is triggered by alterations in the hypothalamic-pituitary-gonadal axis. Erectile dysfunction (ED) is another common disorder in men that involves an alteration in erectile response-organic, relational, or psychological. The incidence of hypogonadism and ED is common in men aged over 40 years. Hypogonadism (including late-onset hypogonadism) and ED may be linked to several environmental factors-induced oxidative stresses. The factors mainly include exposure to pesticides, radiation, air pollution, heavy metals and other endocrine-disrupting chemicals. These environmental risk factors may induce oxidative stress and lead to hormonal dysfunctions. To better understand the subject, the study used many keywords, including "hypogonadism", "late-onset hypogonadism", "testosterone", "erectile dysfunction", "reactive oxygen species", "oxidative stress", and "environmental pollution" in major online databases, such as SCOPUS and PUBMED to extract relevant scientific information. Based on these parameters, this review summarizes a comprehensive insight into the important environmental issues that may have a direct or indirect association with hypogonadism and ED in men. The study concludes that environmental factors-induced oxidative stress may cause infertility in men. The hypothesis and outcomes were reviewed critically, and the mechanistic approaches are applied through oxidant-sensitive pathways. This study also provides reccomendations on future therapeutic interventions and protective measures against such adverse environmental factors-induced hypogonadism and ED.

Citing Articles

Association between uric acid/high-density lipoprotein cholesterol ratio and testosterone deficiency in adult American men: findings from the national health and nutrition examination survey 2011-2016.

Xia W, Xie P, Zhuang Q, Zhang M, Shao N, Chen Y BMC Public Health. 2025; 25(1):939.

PMID: 40065268 PMC: 11892185. DOI: 10.1186/s12889-025-22194-5.


Association between the oxidative balance score and testosterone deficiency: a cross-sectional study of the NHANES, 2011-2016.

Liu J, Ma C, Leng Y, Qin J, Zhang P Sci Rep. 2025; 15(1):8040.

PMID: 40055483 PMC: 11889201. DOI: 10.1038/s41598-025-92934-5.


Ameliorative Role of β-Caryophyllene on Antioxidant Biomarkers in a Paroxetine-Induced Model of Male Sexual Dysfunction.

Olopade E, Adefegha S, Alao J, Adepoju A, Fakayode A, Oboh G Basic Clin Pharmacol Toxicol. 2025; 136(3):e70010.

PMID: 39960010 PMC: 11831715. DOI: 10.1111/bcpt.70010.


Association Between Fine Particle Waves and Sexual Function: A Nationwide Cross-Sectional Survey in China.

Zhang W, Qu R, Cheng G, Wang J, Yin T, Liu J Toxics. 2025; 13(1).

PMID: 39853037 PMC: 11769323. DOI: 10.3390/toxics13010039.


Exploring novel drug targets for erectile dysfunction through plasma proteome with genome.

Qiu Z, Cheng L, Wang Q, Dong Z Sex Med. 2025; 12(6):qfae091.

PMID: 39790564 PMC: 11710913. DOI: 10.1093/sexmed/qfae091.


References
1.
Akingbemi B, Youker R, Sottas C, Ge R, Katz E, Klinefelter G . Modulation of rat Leydig cell steroidogenic function by di(2-ethylhexyl)phthalate. Biol Reprod. 2001; 65(4):1252-9. DOI: 10.1095/biolreprod65.4.1252. View

2.
Kimura M, Rabbani Z, Zodda A, Yan H, Jackson I, Polascik T . Role of oxidative stress in a rat model of radiation-induced erectile dysfunction. J Sex Med. 2012; 9(6):1535-49. DOI: 10.1111/j.1743-6109.2012.02716.x. View

3.
Chen H, Cangello D, Benson S, Folmer J, Zhu H, Trush M . Age-related increase in mitochondrial superoxide generation in the testosterone-producing cells of Brown Norway rat testes: relationship to reduced steroidogenic function?. Exp Gerontol. 2001; 36(8):1361-73. DOI: 10.1016/s0531-5565(01)00118-8. View

4.
Sansone A, Romanelli F, Gianfrilli D, Lenzi A . Endocrine evaluation of erectile dysfunction. Endocrine. 2014; 46(3):423-30. DOI: 10.1007/s12020-014-0254-6. View

5.
Scaglione F, Donde S, Hassan T, Jannini E . Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation. Clin Ther. 2017; 39(2):370-377. DOI: 10.1016/j.clinthera.2017.01.001. View